Description
OP2 Drugs (“OP2”) was incorporated in 2015 to develop and market innovative drugs in life threatening unmet medical needs based on already registered molecules, using untapped academic research results.
As a first lead, OP2 is partnering with the IHU Liryc in Bordeaux (France) and the Buck Institute (California, US), to develop a patented product showing a unique therapeutic potential in pediatric cardiology.
OP2 was founded and is driven by a team that has already completed the takeoff of a biotech, gmp-orphan ("GMPO"), with more than €15m raised to register an innovative product for the Wilson's disease, close to the Marketing Authorization in EU, anticipated early 2017, and running a phase 3 clinical trial for the US submission in 2017/2018.
As a first lead, OP2 is partnering with the IHU Liryc in Bordeaux (France) and the Buck Institute (California, US), to develop a patented product showing a unique therapeutic potential in pediatric cardiology.
OP2 was founded and is driven by a team that has already completed the takeoff of a biotech, gmp-orphan ("GMPO"), with more than €15m raised to register an innovative product for the Wilson's disease, close to the Marketing Authorization in EU, anticipated early 2017, and running a phase 3 clinical trial for the US submission in 2017/2018.
